EXEL: exelixis.com Net earnings per share for the last 12 months

Symbol and logo of brand Exelixis (EXEL)

Exelixis, Inc. (EXEL) attracts elite geneticists through generous stock options, while robust patents and FDA approval secure a long-term monopoly for the company. The company's rolling annual earnings per share reflects the business development dynamics, where 3.33 captures the current value of the indicator. Processes are accelerating via AI-driven molecular modeling, although final clinical trials still require physician involvement.

EXEL (Exelixis, Inc.) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/14/2026

Analytical breakdowns for Exelixis, Inc.

- share price and expert price forecast:
Stock Quotes Exelixis, Inc.|EXEL - Fair Value Consensus
- market capitalization information:
Market Valuation Exelixis, Inc.|EXEL - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Exelixis|EXEL - Book Capitalization|Market Value to Book Value Ratio exelixis.com|EXEL - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Exelixis, Inc.|EXEL - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Exelixis Corp|EXEL - Company Cumulative Debt|Debt to Book Value Exelixis, Inc.|EXEL - Amount of Long-Term Liabilities|Company Short-Term Debts Exelixis|Quick Ratio exelixis.com
- net income and valuation multiples indicators:
EXEL - Company Profit|Future Profit Exelixis, Inc.|EXEL - Company Value to Net Income|Projected Price to Earnings Exelixis|EXEL - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Exelixis, Inc.|EXEL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Exelixis|EXEL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months exelixis.com|EXEL - Earnings per share increase in current year|Earnings growth forecast for next year Exelixis, Inc.
- sales and revenue data:
EXEL - Revenue and Sales Volume|Company Projected Revenue Exelixis, Inc.|EXEL - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Exelixis, Inc.
Basic company analysis:Exelixis, Inc. - EXEL
Manufactured products of Exelixis Inc

This indicator measures net income per common share over a rolling year, allowing for an assessment of real value generation efficiency while excluding quarterly fluctuations. Analysis of the rolling annual EPS chart confirms the scaling resilience of Exelixis, Inc., as the development of targeted cancer therapy is protected by humanitarian status and minimal exposure to geopolitical risks.

Who Exelixis, Inc. competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year NUVL (nuvalent.com)|KYMR (Kymera) - Net earnings per share for the last 12 months|IDYA: Earnings per share for the last four quarters|ELVN (Enliven Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ORIC Corp|Earnings per share for the last twelve months Relay Therapeutics (RLAY)|NRIX (nurixtx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) TYRA (Tyra Biosciences)|Net earnings per share for the trailing year Verastem Oncology|Monte Rosa Tx - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cullinan Corp|IMRX (Immuneering Corporation) - Net earnings per share for the last 12 months|CCCC: Earnings per share for the last four quarters|BDTX (Black Diamond Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Repare Therapeutics, Inc. RPTX|Net earnings per share (EPS TTM) PMVP|karyopharm.com - Earnings per share for the last 12 months|Propanc Biopharma - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGMS|AADI: Net earnings per share for the last 12 months|Aileron Therapeutics - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics) - Net earnings per share (EPS TTM)